Status:
NOT_YET_RECRUITING
The Application Value of Spectral CT in the Accurate Staging of Liver Cancer
Lead Sponsor:
Yunnan Cancer Hospital
Conditions:
Liver Cancer
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Spectral CT was used to prospectively collect medical images and clinical data related to liver cancer, evaluate the effect of image quality in the diagnosis of liver cancer, and evaluate the applicat...
Eligibility Criteria
Inclusion
- Undergo a contrast-enhanced Quark Spectral CT scan of the lower abdomen/pelvis within 1 week before treatment.
- Age \> 18 years.
- Patients suspected of having liver cancer.
- Patients who have signed the informed consent form.
Exclusion
- Severe cardiac, pulmonary, or renal insufficiency.
- Allergy to iodine-based contrast agents.
- Inability to cooperate with the CT examination.
- Poor image quality of the Quark Spectral CT scan.
- Women who are pregnant or breastfeeding.
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 31 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06977399
Start Date
June 1 2025
End Date
May 31 2026
Last Update
May 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yunnan Cancer Hospital
Kunming, Yunnan, China, 650118